Update shared on04 Sep 2025
Both Celanese's consensus revenue growth and net profit margin forecasts remained stable, resulting in an unchanged analyst price target of $54.94.
What's in the News
- Celanese and Bentley Mills launched the use of Celanese's VAE ECO-CC emulsions, made from captured CO2, in Bentley’s carpet tile manufacturing to increase sustainability and recycled content.
- Celanese partnered with Meliodays Medical to provide its VitalDose Drug Delivery Platform for the development of MelioOne, a hormone-free non-contraceptive IUD for menstrual pain relief.
- Celanese was dropped from multiple growth-focused Russell indexes, including Russell 1000 Growth, 3000 Growth, Midcap Growth, and Small Cap Comp Growth.
- Celanese was added to the Russell 2500 Value Index and the broader Russell 2500 Index.
Valuation Changes
Summary of Valuation Changes for Celanese
- The Consensus Analyst Price Target remained effectively unchanged, at $54.94.
- The Consensus Revenue Growth forecasts for Celanese remained effectively unchanged, at 1.1% per annum.
- The Net Profit Margin for Celanese remained effectively unchanged, at 7.79%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.